MARKET

EXAS

EXAS

Exact Sciences Corp
NASDAQ
56.90
-0.61
-1.06%
Closed 19:27 02/27 EST
OPEN
57.98
PREV CLOSE
57.51
HIGH
57.98
LOW
56.11
VOLUME
3.12M
TURNOVER
0
52 WEEK HIGH
100.77
52 WEEK LOW
56.11
MARKET CAP
10.33B
P/E (TTM)
-50.2074
1D
5D
1M
3M
1Y
5Y
Exact Sciences (EXAS) Receives a Buy from BTIG
TipRanks · 22h ago
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
TipRanks · 1d ago
Weekly Report: what happened at EXAS last week (0219-0223)?
Weekly Report · 1d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), Teleflex (TFX) and Amgen (AMGN)
Analysts maintain Buy ratings on Exact Sciences, Teleflex and Amgen. The Healthcare sector has received a lot of coverage today as analysts weigh in on the companies. Exacts Sciences has an analyst consensus of Strong Buy, with a price target of $89.77.
TipRanks · 2d ago
Exact Sciences to Participate in March Investor Conference
Exact Sciences Corp. Is a leading provider of cancer screening and diagnostic tests. Management will participate in the TD Cowen 44th Annual Health Care Conference, Boston Fireside chat on March 4, 2024. Exact Sciences invited investors to participate by webcast. The webcast can be accessed at www.exactsciences.com.
Barchart · 2d ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Companies in the Healthcare sector have received a lot of coverage from analysts. Exact Sciences, United Therapeutics and Ionis Pharmaceuticals have been recommended by analysts. The analysts maintain a Buy rating on Exacts Sciences and a Hold on Ionis pharmaceuticals. The company’s shares closed at $57.53 today.
TipRanks · 2d ago
Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $90
Benzinga · 5d ago
Exact Sciences (EXAS) Q4 Loss Narrows, Revenues Rise Y/Y
NASDAQ · 5d ago
More
About EXAS
Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening, MCED Test Development and MRD Test Development. The Company’s products include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test and COVID-19 Testing. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.

Webull offers Exact Sciences Corp stock information, including NASDAQ: EXAS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EXAS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EXAS stock methods without spending real money on the virtual paper trading platform.